NCT00770835View on ClinicalTrials.gov

Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Diabetes Mellitus
Interventions
DRUG

Pioglitazone and Metformin

Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.

DRUG

Glibenclamide and Metformin

Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.

Trial Locations (2)

Unknown

Padua

Pisa

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00770835 - Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus. | Biotech Hunter | Biotech Hunter